FDA WARNING_LETTER - Unknown Company - July 09, 2026

In July 2026, the U.S. Food and Drug Administration (FDA) issued a warning letter to VasoCorp, Inc. following a review of the company"s website conducted in March 2026. The FDA determined that VasoCorp is marketing its products, NeuropAWAY – Nerve Support Formula and NeuropAWAY pm – Nighttime Nerve Support Formula, as unapproved new drugs. Although these items are presented as dietary supplements, the company’s website features claims that suggest they can treat, mitigate, or prevent diseases such as neuropathy, nerve damage, and chronic inflammation. Under the regulatory framework of the Federal Food, Drug, and Cosmetic Act, products intended for medicinal use must undergo an FDA approval process to prove they are safe and effective. Because VasoCorp has not obtained such approval, these products are being sold illegally in interstate commerce. Furthermore, the FDA identified the products as misbranded because they do not provide adequate directions for use. Since the conditions being targeted—such as neuropathic pain—require a professional medical diagnosis and supervision, it is impossible for a layperson to use these products safely without a doctor"s oversight. The FDA has mandated that VasoCorp, Inc. provide a written response within 15 working days. This response must detail the specific corrective actions the company has taken to address these violations and ensure future compliance with federal law. Failure to rectify these issues promptly may result in further legal action, including product seizures or court-ordered injunctions.